Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling.
about
Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients.Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Pharmacogenomics and lung transplantation: clinical implications.Population pharmacokinetics of cyclosporine in chinese cardiac transplant recipients.The effects of diltiazem in renal transplantation patients treated with cyclosporine AThe CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring.ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patientsPharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trialInfluence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.The role of genetics in drug dosingGenes and beans: pharmacogenomics of renal transplant.Individualized immunosuppression in transplant patients: potential role of pharmacogenetics.Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients.The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation.Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics: A systematic review and meta-analysis.Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy.A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway.Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects
P2860
Q34511457-6045DAD7-F67A-4419-8024-DA85E227EB0FQ36029868-3AF97383-F91B-4ECD-92DF-6A044C26522CQ36186945-2A3407EF-3F85-4946-A771-3E924CA9B6CDQ36415330-55657F3E-174C-453E-8B30-82F16C26E516Q36484956-BA023954-A9E8-4FAD-A7FE-E4E9CF220D3EQ36681589-E3E34FBA-4876-4F6C-8A6A-9A80D3812CBCQ36742534-A4A9F4FE-426A-4547-8B9A-83BA93906F97Q36803373-220EE6C5-BDBD-48E0-9632-F38F493141A7Q36916904-911F2694-97AF-4F31-B006-F1D851DAB4FEQ37157896-B5818694-8F52-42C7-99AE-8326697CC095Q37553134-66BC2C4D-8B68-474D-A95B-6AC1115C4D1CQ37737279-032A3008-164F-4EC5-BE04-BDC6672C3870Q37987439-4B40F819-8214-43E8-8ED8-53CC2BF27255Q38104742-C94339D7-CA4C-416D-A81F-1C0A350E402BQ42065624-016EC074-E9FA-461B-AFE6-1CB374C4FD78Q43708659-D164FE9A-2F08-4AAB-8A7E-0A3869010824Q44899003-F31D7165-B738-4DD6-A320-A635A563505EQ44935457-D3EA9696-05AC-4151-A17B-6E8405AADBEDQ45289878-AA50F1B7-5187-4B8E-8CA8-F1960B3095AAQ46841465-CFE2D8B8-0AA3-4058-89DB-9BBF4D5CF42EQ46920548-414671BA-A662-4E03-89F0-839033B58B36Q47108250-E2476ADF-2856-443C-BF9C-74D2C79251F9Q50202874-BE423CB5-0375-43D4-8439-D5E3C9B36442Q51955888-FC848D89-FC7E-4E0F-9DCC-65D29EE2BCDEQ54576089-C82BE308-20C2-4585-97EB-B1365DA0598FQ55107300-EE2F28B8-3980-4404-B955-8FE56606CA9CQ57500309-D6A0E717-FD6B-488A-8516-389D48E0F1BC
P2860
Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Adequate early cyclosporin exp ...... tored by absorption profiling.
@en
Adequate early cyclosporin exp ...... tored by absorption profiling.
@nl
type
label
Adequate early cyclosporin exp ...... tored by absorption profiling.
@en
Adequate early cyclosporin exp ...... tored by absorption profiling.
@nl
prefLabel
Adequate early cyclosporin exp ...... tored by absorption profiling.
@en
Adequate early cyclosporin exp ...... tored by absorption profiling.
@nl
P2093
P2860
P1476
Adequate early cyclosporin exp ...... tored by absorption profiling.
@en
P2093
Belitsky P
Mahalati K
P2860
P304
P356
10.1034/J.1600-6143.2002.20814.X
P407
P577
2002-09-01T00:00:00Z